NCT00619346终止1 期
Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- The primary objective of this study is to establish the safety and tolerability profile of pafuramidine maleate 100 mg BID administered orally for 14 days to healthy subjects.
研究概览
简要总结
This is a phase 1 study to establish the safety and tolerability profile of pafuramidine maleate 100 mg BID administered orally for 14 days to healthy subjects
详细描述
This is a Phase 1, randomized, double-blind, placebo-controlled, parallel treatment single center safety and tolerability study. Subjects who meet all inclusion criteria and none of the exclusion criteria will be randomized in a 4:1 fashion to receive either pafuramidine maleate 100 mg tablets or matching placebo tablets administered twice daily for 14 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female volunteers a minimum of 18 years to 75 years of age
- •Female must be non-lactating and either be of non-child-bearing potential (i.e. sterilized via hysterectomy or bilateral tubal ligation) or if of child-bearing potential, must have a negative human chorionic gonadotropin (hCG) pregnancy test and be practicing effective dual barrier contraceptive method from consent to 42 days after initiation of study drug administration.
- •Negative test for hepatitis B surface antigen, Hepatitis C antibody and HIV 1 and 2 antibody within 14 days prior to admission to this study
- •The subject has provided written informed consent prior to admission into this study.
排除标准
- •History of clinically relevant medical illnesses that in the Investigator opinion may jeopardize subject safety or interfere with participation in the study, including but not limited to hemoglobinopathy, hemophilia, clinically significant retinal abnormalities, liver diseases, chronic pulmonary diseases, significant cardiovascular diseases, diabetes, thyroid diseases, gout, psychiatric or psychological disorders, CNS trauma or active seizure disorders, allergic or immunologically-mediated disorders
- •History of drug or alcohol abuse, (* 10 drinks weekly)
- •Blood donation within 30 days prior to dosing
- •History of drug allergies, anaphylaxis or laryngeal edema
- •Use of any medication within 7 days before dosing with study medication or anticipated need for any medication during the study conduct
- •Use of any investigational medication within 6 weeks prior to dosing with study medication or scheduled to receive an investigational drug other than pafuramidine maleate during the course of this study
- •Clinically significant abnormal laboratory value at screening including CBC, blood chemistry or urinalysis
- •Clinically significant anomalies noted on physical examination or ECG
- •Resting pulse rate of > 100 beats per minute or < 45 beats per minute during the screening period, either supine or standing.
- •Any condition, which compromises ability to give informed consent or to communicate with the Investigator as required for the completion of this study
- •The subject has been previously enrolled in this study. -
研究组 & 干预措施
1
Placebo Comparator
Placebo tablets resembling 100 mg tablet of active drug BID X 14 days
干预措施: Placebo (Drug)
2
Active Comparator
Pafuramidine maleate, 100 mg tablet, BID X 14 days
干预措施: pafuramidine maleate (Drug)
结局指标
主要结局
The primary objective of this study is to establish the safety and tolerability profile of pafuramidine maleate 100 mg BID administered orally for 14 days to healthy subjects.
时间窗: Day 1 - Day 42
次要结局
- The secondary objective of this study is to evaluate the potential effect of pafuramidine maleate on specific analytes that can be assessed by clinical chemistry and hematology testing.(Screening, Day 7, Day 14, Day 21 and Day 42 of the study.)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid TumorsLocally Advanced or Metastatic Solid TumorsNCT03150810BeiGene139
已完成
1 期
Evaluate HM-002-1005 in Subjects With Type 2 Diabetes MellitusDiabetes Mellitus, Type IINCT06498284Hua Medicine Limited40
暂停
1 期
Clinical Study Assessing the Safety, Tolerability, and Pharmacokinetics of Intravenous AZD5099 in Healthy SubjectsHealthyNCT01340183AstraZeneca80
终止
1 期
Study to Assess Tolerability, Safety and Pharmacokinetics of a New DrugHealthyNCT01702675Ache Laboratorios Farmaceuticos S.A.22
已完成
1 期
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent GlioblastomaBrain and Central Nervous System TumorsNCT03150862BeiGene USA, Inc.116